IL6 and metabolic syndrome: Reductions in C-reactive protein, RBC sedimentation rate and Interleukin-6 (IL-6) were significantly greater in the PAZ group compared to placebo, suggesting that PAZ also has a preventive effect on the pro-inflammatory state generally linked to metabolic syndrome, and may be useful for the treatment of other inflammatory disorders.